ALXO ALX Oncology Holdings Inc.: Enterprise Value to EBITDA Ratio

Graphic logo of ALX Oncology Holdings (ALXO)

ALX Oncology Holdings (ALXO) develops therapies to combat tumors by activating the immune system. This market valuation chart for ALX Oncology Holdings (ALXO) reflects the 0.00 metric. The firm's financial standing depends on available reserves and test results, as it currently generates no sales. Within the evorpacept development oncology ecosystem, there is a stable participant base in trials and significant interest from pharmaceutical behemoths under FDA oversight.

ALX Oncology Holdings - ALXO Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for ALX Oncology (ALXO)

Fundamental company analysis:ALXO (ALX Oncology)
Original product of alxoncology.com

For the biotechnological potential of ALX Oncology Holdings (ALXO) and its Evoracept platform, the EV/EBITDA valuation metric serves as a tool for analyzing the cost of capital relative to operational efficiency. This indicator compares the company's total enterprise value with earnings before interest and taxes, allowing investors to determine the actual debt load and identify the risk of margin compression as borrowing costs rise.

Competitor analysis for ALX Oncology Holdings

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell Pharma LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IO Biotech Corp (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple CUE (Cue Biopharma Inc.)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Bio|Liminatus Pharma (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics NV - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics